Post by Aíma

Headline: Strategic Milestone: Aíma and Eurobio Scientific FR partner to transform Cancer Monitoring 🤝 We are thrilled to announce the signing of a Memorandum of Understanding (MoU) between Aíma and Eurobio Scientific FR, a leading developer and distributor of in vitro diagnostics. This strategic collaboration marks the beginning of our partnership to support the international deployment of EXIS—a cutting-edge liquid biopsy solution for Minimal Residual Disease (MRD). 🧬 Why this partnership matters: By combining Aíma’s innovative technology with Eurobio Scientific’s extensive commercial network and technical expertise, we aim to bring high-performance, decentralized diagnostic tools directly to clinical routines. Key highlights of the EXIS technology: - AI-driven, tumor-agnostic cfDNA analysis leveraging genome-wide methylation patterns for highly sensitive ctDNA detection - Oxford Nanopore native methylation workflow without bisulfite or enzymatic conversion - Rapid turnaround time (<72h) to support real-time therapeutic decision-making - Decentralized workflow designed for implementation in clinical laboratories A sincere thank you to Denis Fortier , DALHIA HAMACHE , Audrey Ortiz , and the entire team at Eurobio Scientific for their trust and shared vision in improving patient outcomes through innovation. Cyrille Fleury Benoit Lemaignan #Aima #HealthTech #FrenchTech #Oncologie #Innovation #EurobioScientific  #Diagnostic #CancerResearch #Liquidbiopsy #Cancer #MRD